{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-004971","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.355776+00:00","generated_at":"2026-05-26T04:58:43.000299+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allarity initiates new Phase 2 protocol for stenoparib in advanced ovarian cancer","bullets":["Patient enrollment begins at US sites with new drug product delivered for new Phase 2 protocol.","Two patients in ongoing phase 2 remain on stenoparib for over 17 months without progression.","Protocol incorporates FDA feedback and IRB approval; critical data expected by end of summer 2026 for pivotal trial.","Trial will evaluate stenoparib-DRP companion diagnostic alongside drug for dual regulatory submission.","Targets $9B+ PARP inhibitor market and addresses FDA Project Optimus dose-finding guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-004971","json":"https://secwatch.observer/filing/0001437749-25-004971.json","markdown":"https://secwatch.observer/filing/0001437749-25-004971.md","text":"https://secwatch.observer/filing/0001437749-25-004971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925004971/0001437749-25-004971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925004971/allr20250224_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:58:43.000299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}